PBTZ 169Alternative Names: PBTZ169
Latest Information Update: 13 Nov 2017
Price : *
At a glance
- Originator A. N. Bach Institute of Biochemistry; Ecole Polytechnique Federale de Lausanne.
- Developer NEARMEDIC
- Class Antituberculars
- Mechanism of Action Cell wall inhibitors; DprE1 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Tuberculosis
Most Recent Events
- 07 Nov 2017 Nearmedic suspends enrolment in a phase IIa trial in Tuberculosis (NCT03334734)
- 16 Dec 2016 Phase-II clinical trials in Tuberculosis in Russia (PO) (NCT03334734)